In a randomized clinical trial including 113 youths aged 7 to 17 years with newly diagnosed type 1 diabetes, there was no significant difference in C-peptide levels measured during a mixed-meal tolerance test (a measure of pancreatic beta cell function) 52 weeks after diagnosis between intensive management and standard care groups. Mean time in the target range of 70 to 180 mg/dL, measured with continuous glucose monitoring, at 52 weeks was 78% with intensive management, which included automated insulin delivery, compared with 64% with standard care.

Read the Full Story Here

In a randomized clinical trial including 113 youths aged 7 to 17 years with newly diagnosed type 1 diabetes, there was no significant difference in C-peptide levels measured during a mixed-meal tolerance test (a measure of pancreatic beta cell function) 52 weeks after diagnosis between intensive management and standard care groups. Mean time in the target range of 70 to 180 mg/dL, measured with continuous glucose monitoring, at 52 weeks was 78% with intensive management, which included automated insulin delivery, compared with 64% with standard care.

Read the Full Story Here